BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 21193545)

  • 21. Are plasma levels of visfatin and retinol-binding protein 4 (RBP4) associated with body mass, metabolic and hormonal disturbances in women with polycystic ovary syndrome?
    Olszanecka-Glinianowicz M; Madej P; Zdun D; Bożentowicz-Wikarek M; Sikora J; Chudek J; Skałba P
    Eur J Obstet Gynecol Reprod Biol; 2012 May; 162(1):55-61. PubMed ID: 22397743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Testosterone to dihydrotestosterone ratio as a new biomarker for an adverse metabolic phenotype in the polycystic ovary syndrome.
    Münzker J; Hofer D; Trummer C; Ulbing M; Harger A; Pieber T; Owen L; Keevil B; Brabant G; Lerchbaum E; Obermayer-Pietsch B
    J Clin Endocrinol Metab; 2015 Feb; 100(2):653-60. PubMed ID: 25387259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Study on the relationship between serum adiponectin and insulin resistance in women with polycystic ovary syndrome].
    Yang XF; Ren FR; Guo SP
    Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):261-3. PubMed ID: 16759463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome.
    Kowalska I; Straczkowski M; Nikolajuk A; Adamska A; Karczewska-Kupczewska M; Otziomek E; Wolczynski S; Gorska M
    Hum Reprod; 2007 Jul; 22(7):1824-9. PubMed ID: 17582143
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polycystic ovary syndrome and anti-Müllerian hormone: role of insulin resistance, androgens, obesity and gonadotrophins.
    Cassar S; Teede HJ; Moran LJ; Joham AE; Harrison CL; Strauss BJ; Stepto NK
    Clin Endocrinol (Oxf); 2014 Dec; 81(6):899-906. PubMed ID: 25040369
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of circulating betatrophin concentrations in lean glucose-tolerant women with polycystic ovary syndrome.
    Erol O; Özel MK; Ellidağ HY; Toptaş T; Derbent AU; Yılmaz N
    J Obstet Gynaecol; 2017 Jul; 37(5):633-638. PubMed ID: 28319674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elevated serum levels of free insulin-like growth factor I in polycystic ovary syndrome.
    Thierry van Dessel HJ; Lee PD; Faessen G; Fauser BC; Giudice LC
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3030-5. PubMed ID: 10487660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased activation of nuclear factor kappaB triggers inflammation and insulin resistance in polycystic ovary syndrome.
    González F; Rote NS; Minium J; Kirwan JP
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1508-12. PubMed ID: 16464947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulating high-sensitivity C-reactive protein and soluble CD40 ligand are inter-related in a cohort of women with polycystic ovary syndrome.
    El-Mesallamy HO; Abd El-Razek RS; El-Refaie TA
    Eur J Obstet Gynecol Reprod Biol; 2013 Jun; 168(2):178-82. PubMed ID: 23434327
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CAG repeat polymorphism in androgen receptor gene is not directly associated with polycystic ovary syndrome but influences serum testosterone levels.
    Skrgatic L; Baldani DP; Cerne JZ; Ferk P; Gersak K
    J Steroid Biochem Mol Biol; 2012 Feb; 128(3-5):107-12. PubMed ID: 22107839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study.
    Puurunen J; Piltonen T; Puukka K; Ruokonen A; Savolainen MJ; Bloigu R; Morin-Papunen L; Tapanainen JS
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4798-807. PubMed ID: 24152688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Body fat and insulin resistance independently predict increased serum C-reactive protein in hyperandrogenic women with polycystic ovary syndrome.
    Tosi F; Dorizzi R; Castello R; Maffeis C; Spiazzi G; Zoppini G; Muggeo M; Moghetti P
    Eur J Endocrinol; 2009 Nov; 161(5):737-45. PubMed ID: 19713424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dietary glycemic index is associated with less favorable anthropometric and metabolic profiles in polycystic ovary syndrome women with different phenotypes.
    Graff SK; Mário FM; Alves BC; Spritzer PM
    Fertil Steril; 2013 Oct; 100(4):1081-8. PubMed ID: 23830153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic inflammation and elevated homocysteine levels are associated with increased body mass index in women with polycystic ovary syndrome.
    Guzelmeric K; Alkan N; Pirimoglu M; Unal O; Turan C
    Gynecol Endocrinol; 2007 Sep; 23(9):505-10. PubMed ID: 17852421
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Urinary bisphenol A in women with polycystic ovary syndrome - a possible suppressive effect on steroidogenesis?
    Lazúrová Z; Figurová J; Hubková B; Mašlanková J; Lazúrová I
    Horm Mol Biol Clin Investig; 2021 Jun; 42(3):303-309. PubMed ID: 34118794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myostatin and its association with abdominal obesity, androgen and follistatin levels in women with polycystic ovary syndrome.
    Chen MJ; Han DS; Yang JH; Yang YS; Ho HN; Yang WS
    Hum Reprod; 2012 Aug; 27(8):2476-83. PubMed ID: 22693174
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lean muscle mass in classic or ovulatory PCOS: association with central obesity and insulin resistance.
    Mario FM; do Amarante F; Toscani MK; Spritzer PM
    Exp Clin Endocrinol Diabetes; 2012 Oct; 120(9):511-6. PubMed ID: 22576259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Positive relationship between androgen and the endocrine disruptor, bisphenol A, in normal women and women with ovarian dysfunction.
    Takeuchi T; Tsutsumi O; Ikezuki Y; Takai Y; Taketani Y
    Endocr J; 2004 Apr; 51(2):165-9. PubMed ID: 15118266
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome.
    Yildiz BO; Yarali H; Oguz H; Bayraktar M
    J Clin Endocrinol Metab; 2003 May; 88(5):2031-6. PubMed ID: 12727950
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome.
    Barber TM; Wass JA; McCarthy MI; Franks S
    Clin Endocrinol (Oxf); 2007 Apr; 66(4):513-7. PubMed ID: 17371468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.